TMO
QT54Thermo Fisher Scientific Inc. (NYSE: TMO) is a Healthcare company in the Medical - Diagnostics & Research industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Thermo Fisher Scientific Inc. (NYSE: TMO) is a Healthcare company in the Medical - Diagnostics & Research industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | S&P 500 | P/E | 30.52 | EPS (ttm) | 18.62 | Insider Own | 0.15% | Shs Outstand | 371.62M | Perf Week | 6.72% |
| Market Cap | 211.18B | Forward P/E | 20.81 | EPS next Y | 27.31 | Insider Trans | -3.00% | Shs Float | 370.74M | Perf Month | 15.45% |
| Enterprise Value | 249.66B | PEG | 4.66 | EPS next Q | - | Inst Own | 87.56% | Short Float | 1.43% | Perf Quarter | 21.76% |
| Income | 6.99B | P/S | 4.56 | EPS this Y | 37.47% | Inst Trans | - | Short Ratio | 2.29 | Perf Half Y | -11.13% |
| Sales | 46.34B | P/B | 4.00 | EPS next Y | 9.20% | ROA | 6.17% | Short Interest | 5.30M | Perf YTD | -1.93% |
| Book/sh | - | P/C | 23.39 | EPS next 5Y | 11.13% | ROE | 13.35% | 52W High | 643.99 -11.76% | Perf Year | 21.76% |
| Cash/sh | - | P/FCF | 28.86 | EPS past 3/5Y | 0.19% 2.11% | ROIC | 7.44% | 52W Low | 435.28 30.55% | Perf 3Y | 6.11% |
| Dividend Est. | 1.88 (0.33%) | EV/EBITDA | 22.83 | Sales past 3/5Y | -0.27% 6.70% | Gross Margin | 40.37% | Volatility | 3.34% 2.79% | Perf 5Y | 9.32% |
| Dividend TTM | 1.80 (0.32%) | EV/Sales | 5.39 | EPS Y/Y TTM | 10.04% | Oper. Margin | 17.69% | ATR (14) | 17.75 | Perf 10Y | 260.27% |
| Dividend Ex-Date | Sep 15, 2026 | Quick Ratio | 1.18 | Sales Y/Y TTM | 5.41% | Profit Margin | 15.06% | RSI (14) | 70.82 | Recom | 2.14 |
| Dividend Gr. 3/5Y | 12.75% 14.34% | Current Ratio | 1.55 | EPS Q/Q | 5.63% | SMA20 | 7.79% | Beta | 0.83 | Target Price | 598.92 |
| Payout | 9.49% | Debt/Eq | 0.81 | Sales Q/Q | 6.18% | SMA50 | 15.50% | Rel Volume | 1.23 | Prev Close | 572.32 |
| Employees | 125,000 | LT Debt/Eq | 0.69 | Earnings | Oct 28 | SMA200 | 7.28% | Avg Volume | 2.37M | Price | 568.26 |
| IPO Date | Mar 17, 1980 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 3.65% 1.29% | Net Debt/EBITDA | 3.52 | Volume | 2,919,132 | Change | -0.71% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-24-26 | Reiterated | Morgan Stanley | Overweight | $620 → $650 |
| Jul-24-26 | Reiterated | RBC Capital | Sector Perform | $490 → $580 |
| Jul-23-26 | Reiterated | Jefferies | Hold | $585 → $630 |
| Jul-06-26 | Reiterated | Evercore ISI Group | Outperform | $650 → $570 |
| Jun-26-26 | Resumed | Bernstein | Market Perform | $520 |
| Jun-11-26 | Initiated | Piper Sandler | Neutral | $510 |
| Jun-03-26 | Downgrade | HSBC | Buy → Hold | $670 → $540 |
| May-14-26 | Resumed | RBC Capital | Sector Perform | $561 → $490 |
| Apr-27-26 | Reiterated | Morgan Stanley | Overweight | $670 → $620 |
| Apr-24-26 | Reiterated | Stifel Nicolaus | Buy | $700 → $600 |
Thermo Fisher Scientific Inc. is a global leader in scientific services, providing a comprehensive range of offerings that include life sciences solutions, advanced analytical instruments, specialized diagnostic products, and an extensive portfolio of laboratory supplies and biopharmaceutical services. The company's reach extends across North America, Europe, Asia-Pacific, and other international markets. Its Life Sciences Solutions division furnishes researchers with essential reagents, state-of-the-art instruments, and consumables vital for biological and medical exploration, the development and manufacturing of therapeutics and vaccines, and the detection of infections and various diseases. This segment encompasses bioscience, genetic science, and bioproduction technologies, serving a broad spectrum of clients in the pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and governmental sectors. The Analytical Instruments segment delivers a variety of precision instruments, consumables, software, and support services to pharmaceutical, biotechnology, academic, governmental, environmental, and industrial research environments, as well as clinical laboratories. The Specialty Diagnostics segment offers an array of diagnostic tools, including liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, alongside calibrators, controls, protein detection assays, and accompanying instruments. This also features the creation and distribution of complete blood test systems to aid in the clinical diagnosis and monitoring of allergies, asthma, and autoimmune diseases. Furthermore, it provides dehydrated and prepared culture media, specimen collection and transport systems, related instrumentation and consumables, human leukocyte antigen (HLA) typing and testing crucial for the organ transplant sector, and other healthcare products. Lastly, the Laboratory Products and Biopharma Services segment supplies laboratory equipment, serves the research and safety markets through its channels, and offers extensive pharmaceutical services, encompassing clinical research support. The company's products and services are distributed through a dedicated direct sales team, customer service professionals, online commerce platforms, and a network of third-party distributors. Its recognized brands include Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD. Thermo Fisher Scientific Inc. was established in 1956 and is headquartered in Waltham, Massachusetts.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 46,336 | 44,556 | 42,879 | 42,857 | 44,915 | 39,211 | 32,218 | 25,542 | 24,358 | |
| Cost of Goods Sold Incl. D&A | 27,629 | 27,778 | 25,151 | 25,663 | 25,904 | 19,577 | 16,191 | 14,198 | 13,370 | |
| Gross Profit | 18,707 | 16,778 | 17,728 | 17,194 | 19,011 | 19,634 | 16,027 | 11,344 | 10,988 | |
| Selling, General and Administrative Excl. Other | 8,049 | 7,272 | 8,676 | 8,411 | 9,015 | 7,910 | 6,949 | 6,062 | 6,028 | |
| Research and Development | 1,404 | 1,397 | 1,390 | 1,337 | 1,471 | 1,406 | 1,181 | 1,003 | 967 | |
| Other Operating Expense | 1,062 | 0 | 0 | 0 | 0 | 0 | 0 | 20 | 121 | |
| Operating Income | 8,195 | 8,109 | 7,662 | 7,446 | 8,525 | 10,318 | 7,897 | 4,259 | 3,872 | |
| Interest Expense | 1,467 | 1,419 | 1,654 | 1,491 | 726 | 536 | 553 | 676 | 667 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 881 | 577 | 987 | 284 | -136 | -945 | -117 | 487 | 57 | |
| Net Income Before Taxes | 7,609 | 7,267 | 6,995 | 6,239 | 7,663 | 8,837 | 7,227 | 4,070 | 3,262 | |
| Income Taxes | 597 | 547 | 657 | 284 | 703 | 1,109 | 850 | 374 | 324 | |
| Consolidated Net Income | 6,978 | 6,737 | 6,335 | 5,995 | 6,950 | 7,725 | 6,375 | 3,696 | 2,938 | |
| Net Income From Continuing Operations | 7,012 | 6,720 | 6,338 | 5,955 | 6,960 | 7,728 | 6,377 | 3,696 | 2,938 | |
| Net Income | 6,978 | 6,737 | 6,335 | 5,995 | 6,950 | 7,725 | 6,375 | 3,696 | 2,938 | |
| EPS (Recurring) | 18.62 | 17.77 | 16.58 | 15.53 | 17.73 | 19.61 | 16.10 | 9.24 | 7.31 | |
| EPS (Basic, Before Extraordinaries) | 18.62 | 17.77 | 16.58 | 15.53 | 17.73 | 19.61 | 16.10 | 9.24 | 7.31 | |
| EPS (Diluted) | 18.59 | 17.74 | 16.53 | 15.45 | 17.64 | 19.46 | 15.98 | 9.17 | 7.24 | |
| EBITDA | 10,935 | 11,466 | 11,800 | 11,195 | 11,942 | 11,969 | 10,108 | 7,023 | 6,195 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 30.57 | 32.66 | 31.47 | 34.36 | 31.22 | 34.29 | 29.15 | 35.43 | 30.91 | |
| Price To Sales Ratio | 4.55 | 4.89 | 4.63 | 4.78 | 4.81 | 6.70 | 5.73 | 5.09 | 3.69 | |
| Gross Margin | 40.37 | 37.66 | 41.34 | 40.12 | 42.33 | 50.07 | 49.75 | 44.41 | 45.11 | |
| Operating Margin | 17.69 | 18.20 | 17.87 | 17.37 | 18.98 | 26.31 | 24.51 | 16.67 | 15.90 | |
| Net Margin | 15.06 | 15.12 | 14.77 | 13.99 | 15.47 | 19.70 | 19.79 | 14.47 | 12.06 | |
| Shares Outstanding | 371 | 376 | 382 | 386 | 392 | 394 | 396 | 400 | 402 | |
| Market Capitalization | 210,824 | 217,873 | 198,728 | 204,885 | 215,870 | 262,893 | 184,449 | 129,948 | 89,964 | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Pettiti Gianluca | President & COO | Apr 27 '26 | Sale | 462.66 | 400 | 185,064 | 25,051 | Apr 29 |
| Shafer Michael D | Executive Vice President | Mar 11 '26 | Sale | 499.40 | 1,607 | 802,536 | 20,950 | Mar 12 |
| CASPER MARC N | Chairman & CEO | Mar 05 '26 | Sale | 514.82 | 4,000 | 2,059,261 | 123,925 | Mar 09 |
| CASPER MARC N | Chairman & CEO | Mar 05 '26 | Option Exercise | 309.63 | 4,000 | 1,238,520 | 127,925 | Mar 09 |
| CASPER MARC N | Chairman & CEO | Mar 04 '26 | Option Exercise | 309.63 | 5,000 | 1,548,150 | 128,925 | Mar 05 |
| CASPER MARC N | Chairman & CEO | Mar 04 '26 | Sale | 512.40 | 5,000 | 2,561,994 | 123,925 | Mar 05 |
| CASPER MARC N | Chairman & CEO | Mar 03 '26 | Sale | 503.10 | 5,000 | 2,515,494 | 123,925 | Mar 05 |
| CASPER MARC N | Chairman & CEO | Mar 03 '26 | Option Exercise | 309.63 | 5,000 | 1,548,150 | 49,550 | Mar 05 |
| Pettiti Gianluca | Executive Vice President | Feb 09 '26 | Sale | 541.20 | 400 | 216,480 | 20,752 | Feb 11 |
| Lagarde Michel | Executive Vice President & COO | Dec 04 '25 | Option Exercise | 120.07 | 40,683 | 4,884,675 | 106,163 | Dec 05 |
| Lagarde Michel | Executive Vice President & COO | Dec 04 '25 | Sale | 563.56 | 22,046 | 12,424,244 | 84,117 | Dec 05 |
| Lagarde Michel | Executive Vice President & COO | Dec 03 '25 | Option Exercise | 105.17 | 68,000 | 7,151,560 | 97,480 | Dec 04 |
| Lagarde Michel | Executive Vice President & COO | Dec 03 '25 | Sale | 583.39 | 32,000 | 18,668,526 | 65,480 | Dec 04 |
| Lagarde Michel | Executive Vice President & COO | Dec 02 '25 | Option Exercise | 105.17 | 36,000 | 3,786,120 | 59,480 | Dec 04 |
| Lagarde Michel | Executive Vice President & COO | Dec 02 '25 | Sale | 581.92 | 30,000 | 17,457,600 | 29,480 | Dec 04 |